McCall Todd D, MacDonald Joel D
Department of Neurosurgery, University of Utah, Salt Lake City 84106, USA.
Neurosurgery. 2006 Sep;59(3):634-40; discussion 634-40. doi: 10.1227/01.NEU.0000227570.40402.77.
Intrathecal baclofen can reduce congenital and posttraumatic spasticity. Traditionally, the catheter tip for baclofen delivery is placed in a low thoracic position, which can result in a lumbar-to-cisternal cerebrospinal fluid baclofen concentration gradient. We investigated whether more rostral catheter placement was technically feasible, safe, and able to control upper extremity spasticity.
The records of 48 patients with a baclofen pump were reviewed retrospectively to evaluate the safety and efficacy of cervically placed intrathecal catheters for baclofen administration. Twenty-three patients had a catheter located in a cervical position and 25 had a catheter in a thoracic position (control group). Complications, including baclofen overdose, mechanical failures, and infections, were noted. Pre- and postoperative Ashworth scores were determined by a physical therapist using a standardized protocol.
The mean duration of the follow-up period was 10 months. The groups were not significantly different in patient age, baclofen dose, or duration of follow-up, but differed somewhat in the causes of spasticity. For patients with a cervical catheter tip position, upper extremity Ashworth scores decreased significantly from 4.0 +/- 0.8 (standard deviation) preoperatively to 3.0 +/- 0.9 postoperatively (P = 0.003). In both groups, lower extremity spasticity was significantly reduced. Postoperatively, one patient with a cervical catheter developed aspiration pneumonia, possibly because of sedation. Other complications included hardware infections, mechanical malfunctions, and pseudomeningoceles.
In this series, placement of intrathecal baclofen catheters in the cervical region resulted in equal control of spasticity in the upper and lower extremities and did not increase complications related to the catheter position.
鞘内注射巴氯芬可减轻先天性和创伤后痉挛。传统上,用于输送巴氯芬的导管尖端置于胸段低位,这可能导致腰段至脑池的脑脊液中巴氯芬浓度梯度。我们研究了将导管置于更高节段是否在技术上可行、安全且能够控制上肢痉挛。
回顾性分析48例使用巴氯芬泵患者的记录,以评估颈段放置鞘内导管给予巴氯芬的安全性和有效性。23例患者的导管位于颈段,25例患者的导管位于胸段(对照组)。记录并发症,包括巴氯芬过量、机械故障和感染。物理治疗师采用标准化方案测定术前和术后的Ashworth评分。
平均随访期为10个月。两组患者在年龄、巴氯芬剂量或随访时间上无显著差异,但在痉挛原因上略有不同。对于导管尖端位于颈段的患者,上肢Ashworth评分从术前的4.0±0.8(标准差)显著降至术后的3.0±0.9(P = 0.003)。两组患者的下肢痉挛均显著减轻。术后,1例颈段导管患者发生吸入性肺炎,可能与镇静有关。其他并发症包括硬件感染、机械故障和假性脑脊膜膨出。
在本系列研究中,将鞘内巴氯芬导管置于颈段可同等程度地控制上下肢痉挛,且不会增加与导管位置相关的并发症。